Brought to you by:
Powered by wagescape.com
Labor Market Pulse
Fond du Lac, WI Metro Edition
Focus: LIFE SCI
Fond du Lac jobs shrink while life sciences hiring stays national-tight.
3.2%
Fond du Lac MSA unemployment
Up from stable readings; WI statewide at 2.7-2.9%
-50 jobs/month avg
Metro job trend 2026
Weakest since 2024; below 2019 employment levels
64%
Biopharma active recruiting
Despite Sept layoffs at BioMarin, Bristol Myers nationally
$79,796
WI biotech average compensation
Well below Boston/Bay Area premium markets
This Month's Takeaways
Local job losses mask a tighter specialized-talent reality.
Fond du Lac's broader labor market is softening, but the roles life sciences leaders actually compete for — regulatory, CMC, quality — sit in a national market still running hot, with 41% of biopharma organizations expecting more open roles this fall. Local unemployment ticking to 3.2% should not be read as easing pressure on scientific or regulatory hiring.
Wisconsin's pay discount is a recruiting tool with limits.
Average biotech compensation of roughly $79,796 statewide, well below coastal hubs, helps retention economics but does little against scarce specialties like cell/gene CMC or clinical pharmacology where national premiums reach $220K-$520K for director-level process development. Relying on geographic pay discount alone risks losing bids for the hardest-to-fill roles to remote-eligible employers.
Outsourcing capacity nearby changes the build-vs-buy math.
Catalent's Madison site, supporting work from research through early manufacturing, gives Fond du Lac-area organizations a credible CDMO alternative within the state rather than defaulting to coastal or international partners. Headcount planning for quality and process development should weigh this regional capacity before committing to internal build-out in a soft local labor market.
Low-hire, low-fire Wisconsin conditions buy a narrow planning window.
Statewide payroll growth remains muted and WARN activity is down 7% year over year, suggesting reduced poaching risk on existing R&D and QA staff through year-end. That window is likely temporary given accelerating national biopharma recruiting activity, and should inform timing on retention adjustments rather than delay them indefinitely.
Local Labor Conditions
Fond du Lac MSA employment continues to contract, averaging a loss of 50 jobs per month through 2026 with the unemployment rate ticking up to 3.2% in August, even as statewide unemployment holds near a two-decade low of 2.7-3.2%. Local softness is concentrated in manufacturing and trade sectors rather than life sciences specifically, but the metro's thin specialized-science labor pool means any R&D, quality, or regulatory opening still draws from a regional talent base stretched by Madison and Milwaukee competition.
Leadership & Talent Implications
Metro-level job losses do not reflect life sciences demand — national data shows 64% of biopharma organizations still actively recruiting even amid September layoff announcements at firms like BioMarin and Bristol Myers, meaning Fond du Lac-based employers compete against a national floor on regulatory, CMC, and quality talent regardless of local softness. Wisconsin's below-coastal compensation positioning (average biotech pay of $79,796 versus Boston/Bay Area premiums) remains a retention asset only if paired with credible internal mobility, since scarce specialties like DMPK, clinical pharmacology, and manufacturing validation will not clear through local hiring alone. Consider evaluating whether current build-vs-outsource assumptions still hold for CMC and quality roles, given that Catalent's Madison facility signals viable CDMO capacity within commuting distance of the metro.
